AVITA Medical (FRA:51KA) Long-Term Capital Lease Obligation : €2.33 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Long-Term Capital Lease Obligation?

AVITA Medical's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.33 Mil.

AVITA Medical's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€1.73 Mil) to Dec. 2023 (€1.56 Mil) but then increased from Dec. 2023 (€1.56 Mil) to Mar. 2024 (€2.33 Mil).

AVITA Medical's annual Long-Term Capital Lease Obligation declined from Jun. 2021 (€0.73 Mil) to Dec. 2022 (€0.29 Mil) but then increased from Dec. 2022 (€0.29 Mil) to Dec. 2023 (€1.56 Mil).

AVITA Medical Long-Term Capital Lease Obligation Historical Data

The historical data trend for AVITA Medical's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Long-Term Capital Lease Obligation Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.70

0.73

0.29

1.56

AVITA Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.15	0.97	1.73	1.56	2.33

AVITA Medical (FRA:51KA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

AVITA Medical Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (FRA:51KA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (FRA:51KA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RCEL:USA AVHHL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.

AVITA Medical (FRA:51KA) Headlines

No Headlines